Real-World Clinical Characteristics, Management, and Outcomes of 44 Paediatric Patients with Hypopigmented Mycosis Fungoides.
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
14
12
2022
accepted:
19
06
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
Hypopigmented mycosis fungoides is a rare form of mycosis fungoides that is characterized by achromic lesions, early onset of disease, a predilection for darker skinned populations, and a predominance of CD8+ T cells. Due to the rarity and heterogeneous presentation of hypopigmented mycosis fungoides, there are no criteria that clearly define the clinical characteristics and treatment regimens for this condition. This retrospective study of 44 paediatric patients with hypopigmented mycosis fungoides aimed to summarize their epidemiological and clinical characteristics and assess the effectiveness and safety of different treatment regimens. Clinical manifestations were further classified into 3 morphological groups: hypopigmented lesions, papules overlying hypopigmented lesions, and erythematous plaques overlying hypopigmented lesions. In addition, the results of this study suggest that interferon alpha might be an effective and well-tolerated therapy that could shorten the treatment time to complete response compared with other treatments. Maintenance therapy and long-term follow-up reduced the recurrence rate.
Identifiants
pubmed: 37606155
doi: 10.2340/actadv.v103.6226
pmc: PMC10461309
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv6226Références
J Am Acad Dermatol. 2003 Aug;49(2):264-70
pubmed: 12894075
Cancer. 2023 Feb 15;129(4):541-550
pubmed: 36523150
Int J Dermatol. 2018 Mar;57(3):306-312
pubmed: 29318586
Cancers (Basel). 2020 Jul 22;12(8):
pubmed: 32707930
Am J Dermatopathol. 2021 Apr 1;43(4):259-265
pubmed: 33201017
J Am Acad Dermatol. 2014 Jun;70(6):993-1001
pubmed: 24629999
J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2
pubmed: 24438969
Dermatol Ther. 2003;16(4):311-21
pubmed: 14686974
Cutis. 2001 Feb;67(2):133-8
pubmed: 11236223
J Cutan Pathol. 2013 Apr;40(4):397-404
pubmed: 23379648
J Eur Acad Dermatol Venereol. 2017 May;31(5):808-814
pubmed: 27515575
J Cutan Pathol. 2013 Nov;40(11):924-34
pubmed: 24320808
Br J Dermatol. 2021 Aug;185(2):419-427
pubmed: 33400272
J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):33-9
pubmed: 10607317
Blood. 1998 Nov 15;92(10):3578-81
pubmed: 9808550
Ann Diagn Pathol. 2017 Jun;28:54-59
pubmed: 28648940
Dermatology. 2014;229(3):271-4
pubmed: 25323446
An Bras Dermatol. 2013 Nov-Dec;88(6):954-60
pubmed: 24474105
Australas J Dermatol. 2021 Aug;62(3):e419-e420
pubmed: 33788252
Indian J Dermatol Venereol Leprol. 2011 Mar-Apr;77(2):167-73
pubmed: 21393946
Int Immunopharmacol. 2019 Dec;77:105999
pubmed: 31704289
Blood. 2022 Aug 4;140(5):419-437
pubmed: 34758074
Photodermatol Photoimmunol Photomed. 2012 Aug;28(4):181-6
pubmed: 23017170
J Clin Pathol. 2018 Dec;71(12):1072-1077
pubmed: 30171087
Dermatol Clin. 2015 Oct;33(4):731-45
pubmed: 26433845
Blood. 2019 Apr 18;133(16):1703-1714
pubmed: 30635287
J Eur Acad Dermatol Venereol. 2022 May;36(5):671-679
pubmed: 35080278
Br J Dermatol. 2021 Sep;185(3):679-680
pubmed: 33942285
J Cutan Pathol. 2014 Feb;41(2):101-7
pubmed: 24219812
Clin Exp Dermatol. 2012 Mar;37(2):149-52
pubmed: 22276982
J Clin Oncol. 2011 Jun 20;29(18):2598-607
pubmed: 21576639
Nat Rev Dis Primers. 2021 Aug 26;7(1):61
pubmed: 34446710
Clin Cosmet Investig Dermatol. 2022 Jul 04;15:1259-1264
pubmed: 35815242
Br J Dermatol. 2022 Aug;187(2):234-243
pubmed: 35194801